Sei Investments Co. Acquires 33,508 Shares of Roivant Sciences Ltd. $ROIV

Sei Investments Co. boosted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 38.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 120,326 shares of the company’s stock after buying an additional 33,508 shares during the quarter. Sei Investments Co.’s holdings in Roivant Sciences were worth $3,333,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Cetera Investment Advisers grew its holdings in shares of Roivant Sciences by 8.2% during the 1st quarter. Cetera Investment Advisers now owns 169,445 shares of the company’s stock valued at $4,694,000 after purchasing an additional 12,873 shares during the last quarter. First Trust Advisors LP lifted its stake in Roivant Sciences by 74.8% in the 1st quarter. First Trust Advisors LP now owns 455,865 shares of the company’s stock valued at $12,627,000 after purchasing an additional 195,101 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Roivant Sciences by 94.1% in the first quarter. PNC Financial Services Group Inc. now owns 26,138 shares of the company’s stock valued at $724,000 after buying an additional 12,672 shares in the last quarter. Meeder Advisory Services Inc. acquired a new stake in Roivant Sciences in the first quarter valued at approximately $227,000. Finally, Parallel Advisors LLC grew its stake in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after buying an additional 520 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Up 3.5%

Shares of Roivant Sciences stock opened at $36.34 on Friday. The stock has a market cap of $26.14 billion, a price-to-earnings ratio of -68.57 and a beta of 1.12. Roivant Sciences Ltd. has a twelve month low of $10.90 and a twelve month high of $37.00. The company’s fifty day moving average is $33.13 and its 200 day moving average is $29.46.

Analyst Upgrades and Downgrades

ROIV has been the subject of a number of research reports. HC Wainwright increased their price target on Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Citigroup increased their target price on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Leerink Partners set a $42.00 price target on Roivant Sciences in a research note on Thursday, May 21st. Finally, Guggenheim boosted their price target on Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.77.

More Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Guggenheim raised its price target to $42 from $36 and assigned a “Buy” rating. The revision implies meaningful upside and provides a clear near-term bullish catalyst for Roivant Sciences (ROIV). Benzinga analyst upgrade
• Positive Sentiment: Roivant said it expects to launch brepocitinib for dermatomyositis by the end of September, a milestone that could improve confidence in the company’s commercialization strategy. It also plans to target cutaneous sarcoidosis, with Phase 3 data expected in 2028. Brepocitinib launch and pipeline update
• Positive Sentiment: Roivant’s subsidiary Immunovant reported that IMVT-1402 development remains on schedule across several autoimmune indications, including Graves’ disease and myasthenia gravis. Its cash balance is expected to fund operations through a potential Graves’ disease launch, reducing near-term financing concerns. Immunovant corporate update

Insider Buying and Selling at Roivant Sciences

In related news, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the transaction, the director directly owned 16,474 shares of the company’s stock, valued at $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $34.95, for a total transaction of $6,990,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $56,376,551.85. The trade was a 11.03% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 2,055,913 shares of company stock worth $69,639,633. Insiders own 8.80% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.